Understanding how DDX5 affects hepatitis B virus and liver cancer development
Role of DDX5 in Hepatitis B virus transcription and hepatocarcinogenesis
This study is looking at a protein called DDX5 to see how it affects the immune system and gene activity in people with hepatitis B, helping us understand why some of them might develop liver cancer, with the hope of finding new ways to treat this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-10789936 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called DDX5 in the context of hepatitis B virus (HBV) infection and its potential link to liver cancer. The researchers aim to understand how DDX5 influences immune responses and gene expression related to HBV, which could provide insights into why some patients develop liver cancer after infection. By analyzing liver cancer cell lines and identifying proteins that interact with DDX5, the study seeks to uncover mechanisms that could lead to new treatment strategies for HBV-related liver cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with chronic hepatitis B infection or those at risk for HBV-related liver cancer.
Not a fit: Patients without hepatitis B infection or those with liver cancer unrelated to HBV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with hepatitis B and reduce the risk of developing liver cancer.
How similar studies have performed: Previous studies have shown promising results in understanding the role of immune signaling in viral infections, suggesting that this approach could yield valuable insights.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Kazemian, Majid — Purdue University
- Study coordinator: Kazemian, Majid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.